Ipv-Boostrix (Aluminium Phosphate, Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haem)

The vaccine contains inactivated toxoids of diphtheria and tetanus together with pertussis antigens, including filamentous haemagglutinin, adsorbed onto an aluminium phosphate adjuvant. After intramuscular injection, the immune system recognises these antigens, producing specific antibodies and memory cells that neutralise the toxins and prevent infection.

The dose and schedule of Ipv-Boostrix are determined by the prescribing healthcare professional based on age, immunisation history and local guidelines. The product is supplied as a single‑dose injectable suspension for intramuscular administration.

Safety data for Ipv-Boostrix in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Ipv-Boostrix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and the necessary import documentation.

Ipv-Boostrix is an acellular pertussis formulation that includes purified pertussis antigens and an aluminium phosphate adjuvant, offering a safety profile comparable to other modern DTaP vaccines. Compared with whole‑cell formulations, it typically causes fewer local and systemic reactions while providing similar protective efficacy.

Ipv-Boostrix must be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside the recommended range.

The vaccine is supplied as a sterile injectable suspension. It is given by a single intramuscular injection, usually into the deltoid muscle of older children and adults or the anterolateral thigh of infants, following the dosing schedule recommended by health authorities.

Serious adverse events are rare but can include anaphylaxis, severe allergic reactions, high‑grade fever, seizures, and, very rarely, Guillain‑Barré syndrome. Immediate medical attention is required if signs of a severe reaction, such as difficulty breathing, swelling of the face or throat, or persistent high fever, occur after vaccination.

Individuals with a known severe allergy to any component of the vaccine, including aluminium phosphate or the specific toxoids, should not receive Ipv-Boostrix. Those who experienced a severe reaction after a previous dose of a DTaP vaccine should also avoid it unless evaluated by a specialist.